Alexander Mosig
University of Jena
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alexander Mosig.
Nature Communications | 2014
Adrian T. Press; Anja Traeger; Christian Pietsch; Alexander Mosig; Michael Wagner; Mark G. Clemens; Nayla Jbeily; Nicole Koch; Michael Gottschaldt; Nicolas Beziere; Volodymyr Ermolayev; Vasilis Ntziachristos; Jürgen Popp; Michael M. Kessels; Britta Qualmann; Ulrich S. Schubert; Michael Bauer
Efficient delivery of short interfering RNAs reflects a prerequisite for the development of RNA interference therapeutics. Here, we describe highly specific nanoparticles, based on near infrared fluorescent polymethine dye-derived targeting moieties coupled to biodegradable polymers. The fluorescent dye, even when coupled to a nanoparticle, mimics a ligand for hepatic parenchymal uptake transporters resulting in hepatobiliary clearance of approximately 95% of the dye within 45 min. Body distribution, hepatocyte uptake and excretion into bile of the dye itself, or dye-coupled nanoparticles can be tracked by intravital microscopy or even non-invasively by multispectral optoacoustic tomography. Efficacy of delivery is demonstrated in vivo using 3-hydroxy-3-methyl-glutaryl-CoA reductase siRNA as an active payload resulting in a reduction of plasma cholesterol levels if siRNA was formulated into dye-functionalised nanoparticles. This suggests that organ-selective uptake of a near infrared dye can be efficiently transferred to theranostic nanoparticles allowing novel possibilities for personalised silencing of disease-associated genes.
Biofabrication | 2015
Martin Raasch; Knut Rennert; Tobias Jahn; Sven Peters; Thomas Henkel; Otmar Huber; Ingo Schulz; Holger Becker; Stefan Lorkowski; Harald Funke; Alexander Mosig
Hemodynamic forces generated by the blood flow are of central importance for the function of endothelial cells (ECs), which form a biologically active cellular monolayer in blood vessels and serve as a selective barrier for macromolecular permeability. Mechanical stimulation of the endothelial monolayer induces morphological remodeling in its cytoskeleton. For in vitro studies on EC biology culture devices are desirable that simulate conditions of flow in blood vessels and allow flow-based adhesion/permeability assays under optimal perfusion conditions. With this aim we designed a biochip comprising a perfusable membrane that serves as cell culture platform multi-organ-tissue-flow (MOTiF biochip). This biochip allows an effective supply with nutrition medium, discharge of catabolic cell metabolites and defined application of shear stress to ECs under laminar flow conditions. To characterize EC layers cultured in the MOTiF biochip we investigated cell viability, expression of EC marker proteins and cell adhesion molecules of ECs dynamically cultured under low and high shear stress, and compared them with an endothelial culture in established two-dimensionally perfused flow chambers and under static conditions. We show that ECs cultured in the MOTiF biochip form a tight EC monolayer with increased cellular density, enhanced cell layer thickness, presumably as the result of a rapid and effective adaption to shear stress by remodeling of the cytoskeleton. Moreover, endothelial layers in the MOTiF biochip express higher amounts of EC marker proteins von-Willebrand-factor and PECAM-1. EC layers were highly responsive to stimulation with TNFα as detected at the level of ICAM-1, VCAM-1 and E-selectin expression and modulation of endothelial permeability in response to TNFα/IFNγ treatment under flow conditions. Compared to static and two-dimensionally perfused cell culture condition we consider MOTiF biochips as a valuable tool for studying EC biology in vitro under advanced culture conditions more closely resembling the in vivo situation.
Journal of Controlled Release | 2015
Alexandra C. Rinkenauer; Adrian T. Press; Martin Raasch; Christian Pietsch; Simon Schweizer; Simon Schwörer; Karl Lenhard Rudolph; Alexander Mosig; Michael Bauer; Anja Traeger; Ulrich S. Schubert
Polymer-based nanoparticles are promising drug delivery systems allowing the development of new drug and treatment strategies with reduced side effects. However, it remains a challenge to screen for new and effective nanoparticle-based systems in vitro. Important factors influencing the behavior of nanoparticles in vivo cannot be simulated in screening assays in vitro, which still represent the main tools in academic research and pharmaceutical industry. These systems have serious drawbacks in the development of nanoparticle-based drug delivery systems, since they do not consider the highly complex processes influencing nanoparticle clearance, distribution, and uptake in vivo. In particular, the transfer of in vitro nanoparticle performance to in vivo models often fails, demonstrating the urgent need for novel in vitro tools that can imitate aspects of the in vivo situation more accurate. Dynamic cell culture, where cells are cultured and incubated in the presence of shear stress has the potential to bridge this gap by mimicking key-features of organs and vessels. Our approach implements and compares a chip-based dynamic cell culture model to the common static cell culture and mouse model to assess its capability to predict the in vivo success more accurately, by using a well-defined poly((methyl methacrylate)-co-(methacrylic acid)) and poly((methyl methacrylate)-co-(2-dimethylamino ethylmethacrylate)) based nanoparticle library. After characterization in static and dynamic in vitro cell culture we were able to show that physiological conditions such as cell-cell communication of co-cultured endothelial cells and macrophages as well as mechanotransductive signaling through shear stress significantly alter cellular nanoparticle uptake. In addition, it could be demonstrated by using dynamic cell cultures that the in vivo situation is simulated more accurately and thereby can be applied as a novel system to investigate the performance of nanoparticle systems in vivo more reliable.
Scientific Reports | 2016
Marko Gröger; Knut Rennert; Benjamin Giszas; Elisabeth Weiß; Julia Dinger; Harald Funke; Michael Kiehntopf; Frank T. Peters; Amelie Lupp; Michael Bauer; Ralf A. Claus; Otmar Huber; Alexander Mosig
Liver dysfunction is an early event in sepsis-related multi-organ failure. We here report the establishment and characterization of a microfluidically supported in vitro organoid model of the human liver sinusoid. The liver organoid is composed of vascular and hepatocyte cell layers integrating non-parenchymal cells closely reflecting tissue architecture and enables physiological cross-communication in a bio-inspired fashion. Inflammation-associated liver dysfunction was mimicked by stimulation with various agonists of toll-like receptors. TLR-stimulation induced the release of pro- and anti-inflammatory cytokines and diminished expression of endothelial VE-cadherin, hepatic MRP-2 transporter and apolipoprotein B (ApoB), resulting in an inflammation-related endothelial barrier disruption and hepatocellular dysfunction in the liver organoid. However, interaction of the liver organoid with human monocytes attenuated inflammation-related cell responses and restored MRP-2 transporter activity, ApoB expression and albumin/urea production. The cellular events observed in the liver organoid closely resembled pathophysiological responses in the well-established sepsis model of peritoneal contamination and infection (PCI) in mice and clinical observations in human sepsis. We therefore conclude that this human liver organoid model is a valuable tool to investigate sepsis-related liver dysfunction and subsequent immune cell-related tissue repair/remodeling processes.
Journal of Controlled Release | 2016
Christoph Englert; Anne-Kristin Trützschler; Martin Raasch; Tanja Bus; Philipp Borchers; Alexander Mosig; Anja Traeger; Ulrich S. Schubert
The targeted drug delivery to the central nervous system represents one of the major challenges in pharmaceutical formulations since it is strictly limited through the highly selective blood-brain barrier (BBB). l-Glutathione (GSH), a tripeptide and well-known antioxidant, has been studied in the last years as potential candidate to facilitate the receptor-mediated transcytosis of nanocarriers. We thus tested whether GSH decoration of a positively charged polymer, poly(ethylene imine), with this vector enables the transport of genetic material and, simultaneously, the passage through the BBB. In this study, we report the synthesis of GSH conjugated cationic poly(ethylene imine)s via ecologically desirable thiol-ene photo-addition. The copolymers, containing 80% primary or secondary amine groups, respectively, were investigated concerning their bio- and hemocompatibility as well as their ability to cross a hCMEC/D3 endothelial cell layer mimicking the BBB within microfluidically perfused biochips. We demonstrate that BBB passage depends on the used amino-groups and on the GSH ratio. Thereby the copolymer containing secondary amines showed an enhanced performance. We thus conclude that GSH-coupling represents a feasible and promising approach for the functionalization of nanocarriers intended to cross the BBB for the delivery of drugs to the central nervous system.
BMC Microbiology | 2016
Knut Rennert; Peter Otto; Harald Funke; Otmar Huber; Herbert Tomaso; Alexander Mosig
BackgroundFrancisella tularensis, a gram-negative bacterium replicates intracellularly within macrophages and efficiently evades the innate immune response. It is able to infect and replicate within Kupffer cells, specialized tissue macrophages of the liver, and to modulate the immune response upon infection to its own advantage. Studies on Francisella tularensis liver infection were mostly performed in animal models and difficult to extrapolate to the human situation, since human infections and clinical observations are rare.ResultsUsing a human co-culture model of macrophages and hepatocytes we investigated the course of infection of three Francisella tularensis strains (subspecies holarctica – wildtype and live vaccine strain, and mediasiatica - wildtype) and analyzed the immune response triggered upon infection. We observed that hepatocytes support the intracellular replication of Franciscella species in macrophages accompanied by a specific immune response inducing TNFα, IL-1β, IL-6 and fractalkine (CX3CL1) secretion and the induction of apoptosis.ConclusionsWe could demonstrate that this human macrophage / hepatocyte co-culture model reflects strain-specific virulence of Francisella tularensis. We developed a suitable tool for more detailed in vitro studies on the immune response upon liver cell infection by F. tularensis.
Biochemical Pharmacology | 2017
Lea Thomas; Zhigang Rao; Jana Gerstmeier; Martin Raasch; Christina Weinigel; Silke Rummler; Dirk Menche; Rolf Müller; Carlo Pergola; Alexander Mosig; Oliver Werz
Graphical abstract Figure. No Caption available. ABSTRACT Pharmacological interference with vacuolar‐type H(+)‐ATPase (V‐ATPase), a proton‐translocating enzyme involved in protein transport and pH regulation of cell organelles, is considered a potential strategy for cancer therapy. Macrophages are critically involved in tumor progression and may occur as pro‐tumoral M2 phenotype, whereas classically‐activated M1 can inhibit tumor development for example by releasing tumor‐suppressing molecules, including tumor necrosis factor (TNF)&agr;. Here, we show that targeting V‐ATPase by selective inhibitors such as archazolid upregulates the expression and secretion of TNF&agr; in lipopolysaccharide (LPS)‐ or LPS/interferon (INF)&ggr;‐activated M1‐like macrophages derived from human blood monocytes. In contrast, archazolid failed to elevate TNF&agr; production from uncommitted (M0) or interleukin (IL)‐4‐treated M2‐like macrophages. Secretion of other relevant cytokines (i.e., IL‐1&bgr;, IL‐6, IL‐10) or chemokines (i.e. IL‐8 and monocyte chemotactic protein‐1) from M1 was not affected by archazolid. Though V‐ATPase inhibitors elevated the lysosomal pH in M1 comparable to chloroquine or ammonium chloride, the latter agents suppressed TNF&agr; secretion. Archazolid selectively increased TNF&agr; mRNA levels, which was abolished by dexamethasone. Interestingly, archazolid enhanced the phosphorylation and nuclear translocation of the p65 subunit of NF&kgr;B and stimulated phosphorylation of SAPK/JNK. In a microfluidically‐supported human tumor biochip model, archazolid‐treated M1 significantly reduced tumor cell viability. Together, our data show that V‐ATPase inhibition selectively upregulates TNF&agr; production in classically‐activated macrophages along with NF&kgr;B and SAPK/JNK activation. Such increased TNF&agr; release caused by V‐ATPase inhibitors may contribute to tumor suppression in addition to direct targeting cancer cells.
Biomicrofluidics | 2016
Martin Raasch; Knut Rennert; Tobias Jahn; Claudia Gärtner; Gilbert Schönfelder; Otmar Huber; Andrea E. M. Seiler; Alexander Mosig
The development of therapeutic substances to treat diseases of the central nervous system is hampered by the tightness and selectivity of the blood-brain barrier. Moreover, testing of potential drugs is time-consuming and cost-intensive. Here, we established a new microfluidically supported, biochip-based model of the brain endothelial barrier in combination with brain cortical spheroids suitable to detect effects of neuroinflammation upon disruption of the endothelial layer in response to inflammatory signals. Unilateral perfusion of the endothelial cell layer with a cytokine mix comprising tumor necrosis factor, IL-1β, IFNγ, and lipopolysaccharide resulted in a loss of endothelial von Willebrand factor and VE-cadherin expression accompanied with an increased leakage of the endothelial layer and diminished endothelial cell viability. In addition, cytokine treatment caused a loss of neocortex differentiation markers Tbr1, Tbr2, and Pax6 in the cortical spheroids concomitant with reduced cell viability and spheroid integrity. From these observations, we conclude that our endothelial barrier/cortex model is suitable to specifically reflect cytokine-induced effects on barrier integrity and to uncover damage and impairment of cortical tissue development and viability. With all its limitations, the model represents a novel tool to study cross-communication between the brain endothelial barrier and underlying cortical tissue that can be utilized for toxicity and drug screening studies focusing on inflammation and neocortex formation.
Advanced Healthcare Materials | 2018
Marko Gröger; Julia Dinger; Michael Kiehntopf; Frank T. Peters; Ursula Rauen; Alexander Mosig
The liver is a central organ in the metabolization of nutrition, endogenous and exogenous substances, and xenobiotic drugs. The emerging organ-on-chip technology has paved the way to model essential liver functions as well as certain aspects of liver disease in vitro in liver-on-chip models. However, a broader use of this technology in biomedical research is limited by a lack of protocols that enable the short-term preservation of preassembled liver-on-chip models for stocking or delivery to researchers outside the bioengineering community. For the first time, this study tested the ability of hypothermic storage of liver-on-chip models to preserve cell viability, tissue morphology, metabolism and biotransformation activity. In a systematic study with different preservation solutions, liver-on-chip function can be preserved for up to 2 d using a derivative of the tissue preservation solution TiProtec, containing high chloride ion concentrations and the iron chelators LK614 and deferoxamine, supplemented with polyethylene glycol (PEG). Hypothermic storage in this solution represents a promising method to preserve liver-on-chip function for at least 2 d and allows an easier access to liver-on-chip technology and its versatile and flexible use in biomedical research.
International Journal of Cancer | 2017
Daniel Kritsch; Franziska Hoffmann; Daniel Steinbach; Lars Jansen; Stella Mary Photini; Mieczyslaw Gajda; Alexander Mosig; Jürgen Sonnemann; Sven Peters; Margarita Melnikova; Jürgen Thomale; Matthias Dürst; Ib Runnebaum; Norman Häfner
Aim was to identify methylated genes with functional involvement in cisplatin‐resistance development of epithelial ovarian cancer (EOC). Genome‐wide analyses of hypermethylated CpG‐islands in resistant cell lines in combination with qRT‐PCR analyses were used to identify epigenetically silenced genes. EOC‐Type‐II tumors were analyzed for gene methylation and expression and TCGA data were interrogated in‐silico. Experiments revealed 37 commonly hypermethylated genes in resistant cells of which Tribbles 2 (TRIB2) showed the most pronounced downregulation on mRNA level and was characterized further. TRIB2 showed a reactivation after 5′‐Aza‐Cytidine treatment in resistant cells but a cisplatin‐dependent, prominent upregulation on mRNA level in sensitive cells, only. Re‐expression in resistant A2780 cells increased the sensitivity to cisplatin and other DNA‐damaging agents, but not taxanes. Contrary, knockdown of TRIB2 increased resistance to cisplatin in sensitive cells. TRIB2 was involved in the induction of a cisplatin‐dependent cell cycle arrest and apoptosis by influencing p21 and survivin expression. An increased Pt‐DNA‐adduct formation in TRIB2 re‐expressing cells did not translate in higher levels of dsDNA damage (yH2AX‐foci). Thus, TRIB2 is potentially involved in the signal transduction from nucleotide excision repair of intrastrand cross links. Importantly, patient stratification of two homogenous cohorts of EOC‐Type‐II patients from Jena (n = 38) and the TCGA (n = 149) by TRIB2 mRNA expression consistently revealed a significantly decreased PFS for patients with low TRIB2 levels (log‐rank p < 0.05). Tumors from resistant patients expressed the lowest levels of TRIB2. Downregulation of TRIB2 contributes to platin‐resistance and TRIB2 expression should be validated as prognostic and predictive marker for EOC.